| Literature DB >> 35536836 |
Pamela Aguilar-Rodea1,2,3, Gerardo Zúñiga4, René Cerritos5, Benjamín Antonio Rodríguez-Espino6, Uriel Gomez-Ramirez2,7, Carolina G Nolasco-Romero2,7, Beatriz López-Marceliano2, Gerardo E Rodea2, Sandra Mendoza-Elizalde2, Alfonso Reyes-López8, Héctor Olivares Clavijo9, Juan Carlos Vigueras Galindo2, Norma Velázquez-Guadarrama2, Irma Rosas-Pérez3.
Abstract
Pseudomonas aeruginosa has different resistant mechanisms including the constitutive MexAB-OprM efflux pump. Single nucleotide polymorphisms (SNPs) in the mexR, nalC, and nalD repressors of this efflux pump can contribute to antimicrobial resistance; however, it is unknown whether these changes are mainly related to genetic lineages or environmental pressure. This study identifies SNPs in the mexR, nalC, and nalD genes in clinical and environmental isolates of P. aeruginosa (including high-risk clones). Ninety-one P. aeruginosa strains were classified according to their resistance to antibiotics, typified by multilocus sequencing, and mexR, nalC, and nalD genes sequenced for SNPs identification. The mexAB-oprM transcript expression was determined. The 96.7% of the strains were classified as multidrug resistant. Eight strains produced serine carbapenemases, and 11 strains metallo-β-lactamases. Twenty-three new STs and high-risk clones ST111 and ST233 were identified. SNPs in the mexR, nalC, and nalD genes revealed 27 different haplotypes (patterns). Sixty-two mutational changes were identified, 13 non-synonymous. Haplotype 1 was the most frequent (n = 40), and mainly identified in strains ST1725 (33/40), with 57.5% pan drug resistant strains, 36.5% extensive drug resistant and two strains exhibiting serin-carbapenemases. Haplotype 12 (n = 9) was identified in ST233 and phylogenetically related STs, with 100% of the strains exhibiting XDR and 90% producing metallo-β-lactamases. Haplotype 5 was highly associated with XDR and related to dead when compared to ST1725 and ST233 (RRR 23.34; p = 0.009 and RRR 32.01; p = 0.025). A significant relationship between the mexR-nalC-nalD haplotypes and phylogenetically related STs was observed, suggesting mutational changes in these repressors are highly maintained within genetic lineages. In addition, phylogenetically related STs showed similar resistant profiles; however, the resistance was (likely or partly) attributed to the MexAB-OprM efflux pump in 56% of the strains (only 45.05% showed mexA overtranscription), in the remaining strains the resistance could be attributed to carbapenemases or mechanisms including other pumps, since same SNPs in the repressor genes gave rise to different resistance profiles.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35536836 PMCID: PMC9089866 DOI: 10.1371/journal.pone.0266742
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Classification of the P. aeruginosa strains (origin, haplotype, susceptibility, MexAB-OprM phenotype, mexA transcript expression, and carbapenemase production).
| Antibiotics | SP | MexAB-OprM | Transcript expression | Carbapenemase | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | H | ST | GEN | TOB | AK | IMI | MEM | CAZ | CPM | P/T | AZT | CIP | LEV | CB* | FOS* | CS | CB—PaβN | CB + PaβN |
|
|
| S | M | |
| 18H |
| 1725 | S | S | S | S | S | S | S | I |
| I | S |
|
| S | MDR |
|
| * | 0.05 | - | / | / |
| 54H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
| S | XDR |
|
| - | 79.59 | + | - | - |
| 3H |
| 1725 |
|
|
|
|
|
|
| I |
|
|
|
|
|
| XDR |
|
| - | 0.08 | - | - | - |
| 14H |
| 1725 |
|
| I |
|
|
|
| I |
|
|
|
|
| S | XDR |
|
| - | 0.02 | - | - | - |
| 15H |
| 1725 |
|
|
|
|
|
|
| I |
|
|
|
|
| S | XDR |
|
| * | 0.03 | - | - | - |
| 39H |
| 1725 |
|
|
| S |
| I |
|
|
|
| S |
|
|
| XDR |
|
| * | 0.64 | - | - | - |
| 55H |
| 1725 |
|
|
|
|
|
|
| I |
|
|
|
|
|
| XDR |
|
| * | 4.31 | + | - | - |
| 8H |
| 1725 |
|
|
|
|
|
|
| I |
|
|
|
|
|
| XDR |
|
|
| 37.31 | + | ND | ND |
| 53H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
| S | XDR | 64 | 4 | - | 85.93 | + | - | - |
| 38H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
| S | XDR |
|
|
| 1.08 | - | - | - |
| 43H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
| S | XDR |
|
|
| 0.13 | - | - | - |
| 5H |
| 1725 |
|
|
|
|
|
|
| I |
|
|
|
|
|
| XDR |
|
|
| 405.31 | + | ND | ND |
| 25H |
| 1725 |
|
|
|
|
|
|
|
|
|
| I |
|
|
| XDR |
|
|
| 184.10 | + | - | - |
| 6H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| - | 0.17 | - | - | - |
| 7H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| - | 0.07 | - | - | - |
| 30H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| - | 1.66 | - | - | - |
| 31H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| - | 3.02 | + | - | - |
| 37H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| - | 139.32 | + | - | - |
| 11H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * | 0.03 | - | - | - |
| 12H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * | 0.53 | - | - | - |
| 26H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * | 132.43 | + | - | - |
| 36H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * | 513.65 | + | - | - |
| 40H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * | 0.10 | - | - | - |
| 41H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3.82 | + | - | - |
| 50H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.84 | - | - | - |
| 33H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 0.05 | - | - | - |
| 48H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.97 | - | + | - |
| 4H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 0.07 | - | ND | ND |
| 16H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 7.06 | + | - | - |
| 42H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 0.18 | - | - | - |
| 49H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 0.15 | - | ND | ND |
| 35H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 0.35 | - | - | - |
| 51H |
| 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 0.26 | - | + | - |
| 46H |
| 2244 |
|
| S |
|
|
|
|
|
|
|
|
|
|
| XDR |
|
| - | 0.82 | - | + | - |
| 47H † |
| 2245 |
|
|
|
|
|
|
| I |
|
|
|
|
|
| XDR |
|
|
| 6.40 | + | - | - |
| 52H |
| 2247 |
|
|
|
|
|
|
|
|
|
|
|
|
| S | XDR |
|
|
| 1.00 | - | ND | ND |
| 45H |
| 2243 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 14.07 | + | ND | ND |
| 1H |
| 1723 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 0.04 | - | - | - |
| 32H |
| 1730 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 33.00 | + | ND | ND |
| 12A |
| 111 | S | S | S | S | I | S | S | S | S | I | S |
|
|
| MDR |
|
| - | 0.07 | - | / | / |
| 56H | 2 | 1725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4.66 | + | - | - |
| 44H | 3 | 2246 |
|
|
|
|
|
|
| I |
|
|
|
|
|
| XDR |
|
| * | 0.15 | - | - | - |
| 10A | 4 | 2566 | S | S | S | S | I | S |
| S | S | S | S |
|
|
| MDR | 128 | 256 | - | 0.02 | - | / | / |
| 10H |
| 1726 |
|
|
|
|
|
|
|
|
|
|
|
|
| S | XDR |
|
| * | 8.79 | + | - | - |
| 27H |
| 1727 |
| S |
|
|
|
|
|
|
|
|
|
|
|
| XDR |
|
| * | 123.89 | + | - | - |
| 9H |
| 1724 |
|
|
|
|
|
|
| I |
|
|
|
|
|
| XDR |
|
| * | 0.05 | - | - | - |
| 2H |
| 1724 |
|
|
|
|
|
|
| I |
|
|
|
|
| S | XDR |
|
|
| 0.15 | - | - | - |
| 28H |
| 1728 |
|
|
|
|
|
|
| I |
|
|
|
|
| S | XDR |
|
|
| 0.03 | - | - | - |
| 17H | 6 | 1733 | S | S | S | S |
| S | S | S | S | S | S |
|
|
| MDR |
|
|
| 0.07 | - | ND | ND |
| 11A | 7 | 2567 | S | S | S | S | S | S | S | S | I | S | S |
|
|
| MDR |
|
| - | 1.01 | - | / | / |
| 68H |
| 2710 |
|
|
|
|
|
|
| I |
|
|
|
|
|
| XDR |
|
| - | 2.65 | - | + | - |
| 70H |
| 2716 |
|
|
|
|
|
|
| I |
|
|
|
|
|
| XDR |
|
| - | 97.90 | + | + | - |
| 63H |
| 2704 |
|
|
|
|
|
|
| I |
|
|
|
|
|
| XDR |
|
| * | 316.39 | + | ND | ND |
| 67H |
| 2710 |
|
|
|
|
|
|
| R |
|
|
|
|
|
|
|
|
| - | 1041.74 | + | + | - |
| 72H |
| 2731 |
|
|
|
|
|
|
| R |
|
|
|
|
|
|
|
|
| - | 8.81 | + | + | - |
| 69H | 9 | 2713 |
|
|
|
|
|
|
| I |
|
|
|
|
|
| XDR |
|
| - | 2.13 | - | - | + |
| 73H | 10 | 2732 | S | S | S |
|
| S | I | I |
|
|
|
|
|
| MDR |
|
| - | 3.17 | + | - | - |
| 2A | 11 | 2249 | S | S | S | S | S | S | S | S | S | S | S |
|
|
| MDR |
|
| - | 0.48 | - | / | / |
| 9A | 11 | 2565 | S | S | S | S | R | S | S | S | I |
| I |
|
|
| MDR |
|
| - | 2.76 | - | - | - |
| 71H |
| 2559 |
|
|
|
|
|
|
|
| S |
|
|
|
|
| XDR |
|
| - | 231.70 | + | - | + |
| 65H |
| 233 |
|
|
|
|
|
|
|
| S |
|
|
|
|
| XDR |
|
| - | 1485.21 | + | - | + |
| 75H |
| 233 |
|
|
|
|
|
|
| I | S |
|
|
|
|
| XDR |
|
| - | 2.44 | - | - | + |
| 76H |
| 233 |
|
|
|
|
|
|
|
| S |
|
|
|
|
| XDR |
|
| - | 100.34 | + | ND | ND |
| 57H |
| 233 |
|
|
|
|
|
|
|
| S |
|
|
|
|
| XDR |
|
| * | 127.01 | + | - | + |
| 59H |
| 233 |
|
|
|
|
|
|
|
| S |
|
|
|
|
| XDR |
|
| * | 1.47 | - | - | + |
| 77H |
| 233 |
|
|
|
|
|
|
|
| S |
|
|
|
|
| XDR |
|
| * | 44.75 | + | - | + |
| 74H |
| 2560 |
|
|
|
|
|
|
|
| I |
|
|
|
|
| XDR |
|
| - | 50.45 | + | - | + |
| 66H |
| 2559 |
|
|
|
|
|
|
|
| S |
|
|
|
|
| XDR |
|
| - | 4.43 | + | - | + |
| 1A | 13 | 2561 | S | S | S | S |
| S |
| I |
| S | S |
|
| S | MDR |
|
| - | 0.83 | - | ND | ND |
| 23H | 14 | 1736 | S | S | S | S | S | S | S | S | I | I | I |
|
|
| MDR |
|
| * | 30.22 | + | / | / |
| 24H | 14 | 1736 | S | S | S | S | I | S | S | S | S | S | S |
|
|
| MDR |
|
| * | 9.74 | + | / | / |
| 61H | 15 | 2557 | S | S | S | S | S | S | I | S | S | S | S |
|
|
| MDR |
|
| * | 90.93 | + | / | / |
| 13A | 16 | 2568 | S | S | S | S |
| S |
| S | S |
| S |
|
| S | MDR | 128 | 256 | - | 8.30 | + | + | - |
| 64H | 17 | 2709 |
|
| S |
| S |
| S | I | I | S |
|
|
|
| XDR |
|
| * | 89.14 | + | ND | ND |
| 60H | 18 | 2248 |
|
| S |
|
|
|
| I |
| I |
|
|
| S | XDR |
|
| - | 167.88 | + | - | + |
| 62H | 18 | 2558 | I | S |
|
|
|
|
| I |
| I |
|
|
| S | XDR |
|
| - | 6.63 | + | - | + |
| 58H | 19 | 112 |
|
|
| I |
|
|
| S | S | S | S |
|
|
| MDR |
|
|
| 4.23 | + | - | - |
| 22H | 20 | 1735 | S | S | S | S | S | S | S | S | S | S | S |
|
|
| MDR |
|
| * | 0.55 | - | / | / |
| 34H | 21 | 561 | S | S | S | S | S | S | S | S | S | S | S |
|
|
| MDR |
|
| - | 0.10 | - | / | / |
| 13H | 21 | 1737 | S | S | S | S | S | S | S | S | S | S | S |
|
|
| MDR |
|
| - | 0.31 | - | / | / |
| 19H | 22 | 1731 | S | S | S | S | S | S | I | S | S | S | R |
|
| S | MDR |
|
|
| 1.48 | - | / | / |
| 4A | 23 | 2563 | S | S | S |
|
| S | S | S |
| S | S |
|
|
| MDR |
|
| - | 0.88 | - | ND | ND |
| 21H | 24 | 1734 | S | S | S | S | S | S | S | S | S | S | S |
|
|
| MDR |
|
|
| 7.00 | + | / | / |
| 3A | 25 | 2562 | S | S | S |
| S | S | S | S | S | S | S |
|
|
| MDR |
|
| - | 0.02 | - | ND | ND |
| 7A |
| 2250 | S | S | S | S | S | S | S | S | I | S | S |
|
| S | S | 64 | 128 | - | 0.04 | - | / | / |
| 6A |
| 540 | S | S | S | S | S | S | S | S | S | S | I |
|
| S | S |
|
| - | 0.03 | - | / | / |
| 8A |
| 2251 | S | S | S | S | I | S | S | S | S | R | S |
|
|
| MDR |
|
| - | 0.03 | - | / | / |
| 5A |
| 2564 | S | S | S | S |
| S | S | S | S | S | S |
|
|
| MDR |
|
| - | 16.73 | + | - | - |
| 29H |
| 1729 |
|
|
|
|
|
|
|
| S | R | R |
|
|
| XDR |
|
| * | 164.59 | + | - | - |
| 14A |
| 1729 | S | S |
| S |
| S |
| I | R | R | S |
|
|
| XDR |
|
| * | 1.95 | - | ND | ND |
| 20H | 27 | 2226 | S | S | S | S | S | S | S | S | S | S | S |
|
| S | S |
|
| - | 0.07 | - | / | / |
| PAO1 | 549 | S | S | S | S | S | S | S | S | S | S | S | S |
| S | S | 64 | 64 | - | 1.00 | - | / | / | |
ID: origin (H: nosocomial strains; A: environmental strains); patient death outcome: †
H: Haplotype was considered as the DNA sequence from the concatenation of mexR-nalC-nalD genes.
ST: Sequence Type. The ST1725 (most frequent) and the ST233 (high risk clone) are highlighted.
Antibiotic categories: Aminoglycosides (GEN: gentamicin, TOB: tobramycin, AK: amikacin), Carbapenems (IMI: imipenem, MEM: meropenem), Cephalosporins (CAZ: ceftazidime, CPM: cefepime), Penicillins (CB: carbenicillin), Penicillins + β-lactamase inhibitors (P/T: piperacillin-tazobactam), Monobactams (AZT: aztreonam), Fluoroquinolones (CIP: ciprofloxacin, LEV: levofloxacin), Phosphonic Acids (FOS: fosfomycin), Polymyxins (CS: colistin).
SP: Susceptibility: S: sensitive, I: intermediate resistant, R: resistant; S: sensitive; MDR: multidrug resistant, XDR: extensively drug resistant, PDR (highlighted): pan drug resistant.
MexAB-OprM: MexAB-OprM efflux pump phenotypic detection; carbenicillin (CB), a substrate of the pump, was used as reporter antibiotic; CB—PaβN: MIC determined for each strain to CB in the absence of the efflux inhibitor Phe-Arg-β-naphthylamine (PaβN) (50 μg/mL); CB + PaβN: MIC determined for each strain to CB in the presence of the efflux inhibitor PaβN (50 μg/mLg/L); : Elevation of the MIC is caused by the MexAB-OprM efflux pump: +: MexAB-OprM efflux pump is most likely the cause of the elevation of the MIC (values in bold); *: MexAB-OprM efflux pump is contributing in the elevation of the MIC (values in italics); -: MexAB-OprM efflux pump is unlikely to be the cause of the elevation of the MIC or no elevation of the MIC (underlined values).
Transcript expression: mexA: transcript expression level; transcript ratio between the target gene mexA and the reference gene rpsL; : +: mexAB-oprM overtranscription; -: mexAB-oprM basal level.
Carbapenemase: S: serine carbapenemase, M: metallo-β-lactamase, +: presence of carbapenemase; ND: not determined; /: meropenem and imipenem sensitive strain; Carbapenemase-producing test was developed in meropenem and/or imipenem resistant strains.
Number of haplotypes, nucleotide diversity, gene diversity and substitutions identified by gene for the genotyping of the P. aeruginosa strains via MLST.
| MLST | H strains (n = 77) | A strains (n = 14) | H + A (n = 91) |
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
|
| 2882 | 2882 | 2882 | 390 | 498 | 373 | 442 | 366 | 370 | 443 |
|
| 35 | 14 | 48 | 18 | 12 | 14 | 17 | 9 | 14 | 16 |
|
| 0.0067 | 0.0074 | 0.0071 | 0.0099 | 0.0102 | 0.0055 | 0.0036 | 0.0024 | 0.007 | 0.0101 |
|
| 0.0057 | 0.0071 | 0.0064 | 0.0066 | 0.0071 | 0.0063 | 0.0049 | 0.0054 | 0.0059 | 0.0084 |
|
| 0.802 | 1 | 0.858 | 0.769 | 0.751 | 0.766 | 0.678 | 0.557 | 0.777 | 0.779 |
|
| 81 | 65 | 94 | 13 | 18 | 12 | 11 | 10 | 11 | 19 |
H: nosocomial strains; A: environmental strains.
Haplotype was considered as the DNA sequence from the concatenated sequences obtained from the Multilocus Sequence Typing (MLST).
Pi: nucleotide diversity; Eta: theta (per site); Hd: gene diversity; S: substitutions.
Genetic variations (haplotypes) identified in the mexR, nalC and nalD repressor genes in P. aeruginosa strains.
| Haplotype |
|
|
|
|---|---|---|---|
|
| S88S, E109E, Q128Q, Q137Q, | A4A, S5S, A23A, I41I, R43R, G49G, E59E, S118S, Y137Y, A145A, A148A, P149P, | L57L, L99L |
|
| S88S, E109E, Q128Q, Q137Q, | A4A, S5S, A23A, I41I, R43R, G49G, E59E, S118S, Y137Y, A145A, A148A, P149P, | L57L, L99L |
|
| S88S, E109E, Q128Q, Q137Q, | A4A, S5S, A23A, I41I, R43R, G49G, E59E, S118S, A123A, Y137Y, A145A, A148A, P149P, | K26K, L99L, R150R, P159P |
|
| V20V, E109E, Q128Q, Q137Q, | A4A, S5S, A23A, I41I, R43R, G49G, E59E, S118S, A123A, Y137Y, A145A, A148A, P149P, | G45G |
|
| V20V, E109E, Q128Q, Q137Q, | A4A, S5S, A23A, I41I, G49G, E59E, S118S, R120R, A123A, Y137Y, A145A, A148A, P149P, | C92C, L99L, I111I, D180D |
|
| V5V, N6N, P11P, T22T, R32R, S88S, E109E Q128Q, Q137Q, | A4A, S5S, A23A, I41I, G49G, E59E, S118S, Y137Y, A145A, A148A, P149P, | L57L, C92C, L99L, D180D |
|
| V5V, N6N, P11P, R32R, D56D, S88S, E109E, Q128Q, Q137Q, |
|
|
|
| V5V, N6N, P11P, R32R, S88S, E109E, Q128Q, Q137Q, | A23A, |
|
|
| V5V, N6N, P11P, R32R, S88S, E109E, Q128Q, Q137Q, | A23A, |
|
|
| S88S, E109E, Q128Q, Q137Q, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| V126V, Q137Q. |
|
|
|
| L67L |
|
|
|
| L67L |
| A40A. |
|
|
|
|
|
|
| D56D | T86T, V147V, P149P, |
|
|
|
| T86T, V147V, P149P, | F51F, L57L, L99L. |
|
|
| A23A, |
|
|
| D56D | A23A, | D185D |
|
|
| A23A, |
|
|
|
| A4A, S5S, | A168A. |
|
|
| A4A, S5S, A23A, I41I, R43R, G49G, E59E, S118S, A123A, Y137Y, A145A, A148A, P149P, | R150R, P159P, D185D |
|
| V20V, E109E, Q128Q, Q137Q, | A4A, S5S, A23A, I41I, G49G, E59E, F62F, F98F, S118S, Y137Y, A145A, A148A, P149P, A186A, | K26K, A55A, T101T, R150R, P159P |
|
|
| A4A, S5S, A23A, I41I, G49G, E59E, S118S, R120R, A123A, Y137Y, A145A, A148A, P149P, | S77S, L99L |
|
| 11 | 17 | 14 |
|
| 0.00745 | 0.01184 | 0.00376 |
|
| 0.00709 | 0.00906 | 0.00585 |
|
| 0.718 | 0.771 | 0.723 |
|
| 16 | 28 | 18 |
First letter indicates reference strain (P. aeruginosa PAO1) amino acid, the number indicates the amino acid position where the change occurs, and the second letter indicates the amino acid that substitutes the original amino acid. The symbol △means nucleotide deletion. The * means stop codon. Amino acid variation: A: alanine, C: cysteine, D: aspartic acid, E: glutamic acid, F: phenylalanine, G: glycine, H: histidine, I: isoleucine, K: lysine, L: leucine, M: methionine, N: asparagine, P: proline, Q: glutamine, R: Arginine, S: serine, T: threonine, V: valine, W: tryptophan, Y: tyrosine. In bold are non-synonymous substitutions. Pi: nucleotide diversity, Eta: theta (per site), Hd: gene diversity, S: nucleotide substitutions. In haplotype 13 (no SNPs identified), the mexR, nalC and nalD repressor genes of the MexAB-OprM efflux pump sequences were identical to those of P. aeruginosa PAO1. In parenthesis, the number of haplotypes.
Fig 1Phylogenetic network based on the MLST genotyping of the P. aeruginosa strains (ST/haplotypes).
Phylogenetic relationships, evolutionary history, clonal complexes, and relationship between the mexR-nalC-nalD haplotypes and the STs are shown. P. aeruginosa isolates (n = 91, 48 STs, 27 mexR-nalC-nalD haplotypes). Circles represent sequence types (STs); Circumference is based on ST frequency; Two or more strains with the same ST are depicted as fractions in each circle (ST1725, n = 34 strains); Lines connect locus variants; Numbers indicate the number of locus variants among the connected STs. Clonal complexes (CC) formed are highlighted in rectangles and described as I, II, III, IV, V and, VI. STs not grouped into a CC are considered singletons (>3 locus variants with other STs). Numbers inside the circles (1–27) corresponds with the mexR-nalC-nalD haplotype and are colored differently. †: Fatal patient outcome.
Fig 2Phylogenetic network based on the MLST genotyping of the P. aeruginosa strains (ST/haplotypes/resistance).
Relationship between the mexR-nalC-nalD haplotypes, the STs and, the susceptibility profiles are shown. P. aeruginosa isolates (n = 91, 48 STs, 27 mexR-nalC-nalD haplotypes). Circles represent sequence types (STs); Circumference is based on ST frequency; Two or more strains with the same ST, including ST1725 are depicted as fractions in each circle (n = 34 strains); Lines connect locus variants; Numbers indicate the number of locus variants among the connected STs. Clonal complexes (CC) formed are highlighted in rectangles and described as I, II, III, IV, V and, VI. STs not grouped into a CC are considered singletons (>3 locus variants with other STs). Number inside the circles (1–27) corresponds with the mexR-nalC-nalD haplotype and are colored differently. †: Fatal patient outcome. Susceptibility profiles: S (green), sensitive; MDR (yellow), multidrug resistant; XDR (orange), extensively drug resistant; PDR (red), pan drug resistant. *S: Serine carbapenemase; M*: Metallo-β-lactamase.
Fig 3Neighbor-net graph based on the MLST genotyping of the P. aeruginosa strains.
P. aeruginosa isolates (48 STs). Rectangular boxes represent the high probability of extensive homologous recombination. The PHI test detected statistically significant evidence of recombination (p = 0.0). Clonal complexes (CC) formed are highlighted in rectangles and described as (I, II, III, IV, V, and VI). The mexR-nalC-nalD haplotype of each CC is shown.
Fig 4Principal component analysis of the 91 P. aeruginosa strains.
P. aeruginosa isolates (n = 91). Each strain is represented by a colored dot according to mexR-nalC-nalD haplotype (Fig 1). †: Fatal patient outcome. Variables included: Outcome (black vector): living, died; Resistance (purple vector): sensitive (S), multi-drug resistant (MDR), extensively drug resistant (XDR), and pan drug resistant (PDR); ST (blue vector) (n = 48); MexAB-OprM haplotype (mexR-nalC-nalD) (green vector) (n = 27); Isolation site (yellow vector): hospital, environmental; Date (pink vector): 2007–2013; Hospital ward (aqua vector): Stx, surgical therapy; E, emergency room; N, neurology; PICU, pediatric intensive care unit; P, pediatrics; S, surgery; Neph, nephrology; O, oncology; It, internal therapy; C, cardiology; NICU, neonatal intensive care unit; Ne, necropsy; IMed, internal medicine.